This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

ZEPATIER® (elbasvir/grazoprevir)

Power to cure* in People Who Inject Drugs1

Updated on 15/07/2019

HEPATITIS C
tbc

93% SVR for G1+G4 patients on OST, many of whom continued to take recreational drugs1

ZEPATIER 93% SVR image

Approximately 62% of patients in the immediate treatment arm continued to use recreational drugs throughout the trial1

Recreational drug use during C-Edge co-star trial
  • ZEPATIER has no drug-drug interactions with buprenorphine/naloxone and methadone2
  • Concomitant recreational drug use did not affect efficacy of ZEPATIER in patients receiving OST1
  • Patients receiving OST were highly (defined as >95%) adherent to ZEPATIER, due to study protocol, via post-hoc analysis†1
Additional data and C-Edge Co-Star study design

WHO draft global health sector strategy on viral hepatitis, 2016-2021

“A goal of eliminating viral hepatitis as a major public threat by 2030”3

If we are to eliminate hepatitis C as a major public health threat, there are two main impact areas where we need to make progress: we need to reduce the numbers becoming seriously ill or dying from this infection, whilst at the same time reducing the number of people who become newly or re-infected.3


*Cure defined as Cure of HCV infection = Sustained Virologic Response (SVR), the primary endpoint in all studies, was defined as Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) less than the Lower Limit of Quantification (LLOQ) (≤15 IU/ml) at 12 weeks after the cessation of treatment4

** Includes all patients; reinfections counted as failures

C-Edge Co-Star, Full analysis set. 192 out of 199 patients in a post-hoc analysis took >95% of the 84 doses of ZEPATIER administered over 12 weeks1

Related content

 

References

  1. Dore GJ et al. Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy. Ann Intern Med. doi:10.7326/M16-0816.
  2. ZEPATIER Summary of Product Characteristics.
  3. WHO global health sector strategy on viral hepatitis, 2016-2021.
  4. European Association for the Study of Liver. J Hepatol 2018;69;461-511.

Supporting documentation

Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-ZEP-00102 | Date of Preparation: July 2019